Bethany Stevens
Family · Eau Claire, WINPI 1407501638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$743
- Boehringer Ingelheim$532
- Lilly USA, LLC$471
- AbbVie$460
- Bayer$288
- Johnson & Johnson$262
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $743 |
| Boehringer Ingelheim | 29 | $532 |
| Lilly USA, LLC | 32 | $471 |
| AbbVie | 26 | $460 |
| Bayer | 17 | $288 |
| Johnson & Johnson(2 entities) | 14 | $262 |
| AstraZeneca | 10 | $200 |
| Merck | 12 | $180 |
| GSK | 9 | $166 |
| Pfizer | 7 | $143 |
| Dexcom, Inc. | 8 | $143 |
| Regeneron Healthcare Solutions, Inc. | 6 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $100 |
| Exact Sciences | 6 | $89 |
| Mylan Specialty L.p. | 5 | $82 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $80 |
| Sanofi | 3 | $70 |
| Novartis | 4 | $67 |
| Amgen | 4 | $63 |
| Astellas Pharma US Inc | 2 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Biomerieux Inc | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Vertex | 1 | $20 |
| Ardelyx, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
$4,579 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,238 |
| Valsartan | 24 | $456 |
| Duloxetine Hcl | 20 | $368 |
| Atorvastatin Calcium | 39 | $364 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $349 |
| Amlodipine Besylate | 37 | $265 |
| Chlorthalidone | 11 | $228 |
| Levothyroxine Sodium | 26 | $226 |
| Rosuvastatin Calcium | 12 | $174 |
| Cyclobenzaprine Hcl | 19 | $151 |
| Metoprolol Succinate | 13 | $142 |
| Diclofenac Sodium | 11 | $134 |
| Lisinopril | 30 | $134 |
| Omeprazole | 21 | $117 |
| Allopurinol | 13 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $166 | $14,23822 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $14 | $45624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.
Other family in Eau Claire
- Nicole HolmEau Claire$10K
- Carly OvergardEau Claire$5K
- Jennifer OlsonEau Claire$4K
- Stephanie OffordMilwaukee$116K
- Laura SwobodaMenomonee Falls$111K
- Lonniel BainMadison$54K
- Linda WespGlendale$44K
- Andrea BuxtonGreen Bay$36K
- Jani CookGreen Bay$31K
- Tiffany HolleySheboygan$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.